

THE ROLE OF MODERN BIOMARKERS IN DIAGNOSING ANEMIA AND THEIR APPLICATION IN UZBEKISTAN

Ulug'boyeva Odina

University of Business and Science, Department
of Therapeutic Work
24_05 group students

Usmonova Feruza Nematjonovna


Scientific advisor:

<https://doi.org/10.5281/zenodo.15488766>

Abstract: Anemia remains a significant global health challenge, particularly in resource-constrained settings like Uzbekistan, where its multifactorial etiology complicates diagnosis and management. Modern biomarkers, including hepcidin, soluble transferrin receptor (sTfR), reticulocyte hemoglobin content (CHr), erythroferrone, and growth differentiation factor 15 (GDF-15), have transformed anemia diagnostics by offering superior specificity and sensitivity over conventional markers such as hemoglobin and ferritin. These biomarkers enable precise differentiation of anemia subtypes, including iron deficiency anemia (IDA), anemia of chronic disease (ACD), and hemolytic anemias, facilitating targeted therapeutic interventions. This article comprehensively explores the diagnostic utility of these biomarkers, their integration into clinical practice, and the practical challenges and opportunities for their implementation in Uzbekistan, considering the country's healthcare infrastructure, economic limitations, and unique epidemiological profile. By bridging global diagnostic advancements with local needs, this study highlights the transformative potential of biomarkers in enhancing anemia management in Uzbekistan.

Keywords: Anemia, biomarkers, hepcidin, soluble transferrin receptor, reticulocyte hemoglobin content, erythroferrone, growth differentiation factor 15, Uzbekistan, iron deficiency anemia, diagnostic precision

Anemia, defined by a decrease in red blood cell mass or hemoglobin concentration, affects over 1.9 billion people worldwide, with disproportionate prevalence in low- and middle-income countries. In Uzbekistan, anemia is a pressing public health issue, particularly among women of reproductive age, children, and the elderly, driven by nutritional deficiencies, chronic infections, and genetic hemoglobinopathies. Traditional diagnostic tools, such as hemoglobin measurement, serum ferritin, and peripheral blood smears, often fail to distinguish between anemia subtypes due to overlapping clinical features and the influence of confounding factors like inflammation. The emergence of modern biomarkers has revolutionized anemia diagnostics by providing




detailed insights into iron metabolism, erythropoiesis, and underlying pathophysiological processes. This article examines the role of key biomarkers—hepcidin, soluble transferrin receptor (sTfR), reticulocyte hemoglobin content (CHr), erythroferrone, and growth differentiation factor 15 (GDF-15)—in improving diagnostic accuracy and evaluates their feasibility for widespread adoption in Uzbekistan's healthcare system, considering infrastructural, economic, and epidemiological factors.

Hepcidin, a liver-derived peptide hormone, is a master regulator of iron homeostasis, controlling iron absorption and mobilization by degrading ferroportin, the primary iron exporter. In iron deficiency anemia (IDA), low hepcidin levels enhance intestinal iron uptake and macrophage iron release to meet erythropoietic demands. Conversely, in anemia of chronic disease (ACD), elevated hepcidin levels, driven by inflammatory cytokines like interleukin-6, sequester iron in storage sites, limiting its availability for red blood cell production. Hepcidin measurement, typically via enzyme-linked immunosorbent assays (ELISA) or liquid chromatography-mass spectrometry (LC-MS), enables precise differentiation between IDA and ACD, guiding therapeutic decisions such as iron supplementation or anti-inflammatory treatments. However, hepcidin's clinical utility is complicated by its sensitivity to inflammation, renal function, and diurnal fluctuations, necessitating standardized sampling protocols and population-specific reference ranges.

Soluble transferrin receptor (sTfR) is a biomarker of erythropoietic activity and iron status, expressed on erythroid precursors and shed into the bloodstream. Unlike ferritin, sTfR is minimally affected by inflammation, making it an ideal marker for detecting iron deficiency in patients with chronic inflammatory conditions, such as tuberculosis or rheumatoid arthritis, which are prevalent in Uzbekistan. Elevated sTfR levels indicate increased erythroid demand, as seen in IDA or hemolytic anemias, while normal levels are characteristic of ACD. The sTfR/log ferritin index enhances diagnostic specificity by integrating iron stores and erythropoietic activity, offering a robust tool for complex cases. Automated immunoassays for sTfR are standard in high-income countries, but their high cost and requirement for specialized equipment limit their use in Uzbekistan, particularly in rural healthcare facilities.

Reticulocyte hemoglobin content (CHr) measures the hemoglobin content of newly formed red blood cells, providing an early indicator of iron availability for erythropoiesis. CHr is particularly valuable for detecting functional iron deficiency in patients undergoing erythropoiesis-stimulating agent therapy or



those with chronic kidney disease, both of which are increasing in Uzbekistan due to rising non-communicable disease burdens. A CHr value below 28 pg strongly suggests IDA, while normal or elevated values may indicate other anemia etiologies, such as megaloblastic anemia or hemolysis. CHr is measured using advanced hematology analyzers, which are available in major hospitals in Tashkent and Samarkand but scarce in peripheral regions, highlighting disparities in diagnostic capacity.

Erythroferrone, a recently identified biomarker, is an erythroid regulator of iron metabolism, suppressing hepcidin production in response to increased erythropoiesis. Elevated erythroferrone levels are observed in conditions with high erythroid activity, such as thalassemia or hemolytic anemias, which are relevant in Uzbekistan due to the prevalence of hemoglobinopathies in certain ethnic groups. By modulating hepcidin, erythroferrone provides insights into the balance between erythropoiesis and iron availability, offering a complementary diagnostic tool for complex anemias. However, erythroferrone assays are primarily research-based, with limited commercial availability, posing significant barriers to clinical adoption in resource-limited settings.

Growth differentiation factor 15 (GDF-15), a stress-responsive cytokine, is elevated in conditions associated with ineffective erythropoiesis, such as thalassemia, sickle cell disease, and myelodysplastic syndromes. GDF-15 suppresses hepcidin expression, contributing to iron overload in these disorders. Measuring GDF-15 levels, typically via ELISA, can aid in identifying anemias with underlying bone marrow dysfunction, which are often underdiagnosed in Uzbekistan due to limited access to bone marrow aspiration and genetic testing. The integration of GDF-15 with other biomarkers, such as hepcidin and erythroferrone, enhances diagnostic algorithms for rare and hereditary anemias, but its high assay costs and lack of standardized cutoffs limit its routine use.

The application of these biomarkers in Uzbekistan is shaped by a complex interplay of healthcare infrastructure, economic constraints, and epidemiological patterns. Uzbekistan has made significant progress in strengthening its healthcare system, with investments in diagnostic laboratories, medical education, and universal health coverage initiatives. However, disparities between urban and rural healthcare access remain stark, with advanced diagnostic tools concentrated in major cities like Tashkent, Bukhara, and Samarkand. For instance, while hemoglobin testing is nearly ubiquitous, specialized assays for hepcidin, sTfR, or erythroferrone are available only in

select research institutes or private clinics, often at prohibitive costs for the average patient. The reliance on outdated diagnostic methods, such as manual blood smears, in rural clinics further exacerbates diagnostic delays and misdiagnoses.

Economic barriers significantly hinder biomarker adoption. The cost of ELISA kits, LC-MS systems, or advanced hematology analyzers is substantial, and public healthcare budgets in Uzbekistan prioritize essential services over cutting-edge diagnostics. Limited reimbursement policies for specialized tests mean that patients often bear out-of-pocket costs, which is unsustainable given the country's average income levels. Additionally, the lack of locally validated reference ranges for biomarkers complicates their interpretation, as genetic polymorphisms, dietary habits (e.g., low meat consumption), and environmental factors in Central Asia may alter baseline values. For example, studies suggest that Uzbek populations may have distinct iron metabolism profiles due to high prevalence of parasitic infections and micronutrient deficiencies, necessitating tailored diagnostic thresholds.

Epidemiologically, Uzbekistan faces a diverse anemia burden. Iron deficiency anemia, driven by inadequate dietary iron, parasitic infections, and frequent pregnancies, remains the most common form, particularly in rural areas. However, the rising incidence of chronic diseases, including diabetes, cardiovascular disorders, and chronic kidney disease, has increased the prevalence of ACD, requiring biomarkers like sTfR to differentiate it from IDA. Genetic anemias, such as beta-thalassemia and glucose-6-phosphate dehydrogenase deficiency, are significant in regions like Fergana and Khorezm, where consanguineous marriages are more common. Biomarkers like erythroferrone and GDF-15 are critical for diagnosing these conditions, but their limited availability underscores the need for targeted screening programs. Furthermore, the high burden of infectious diseases, including tuberculosis and hepatitis, complicates anemia diagnosis, as inflammation alters traditional marker levels, reinforcing the value of inflammation-independent biomarkers like sTfR and CHr.

Opportunities to integrate modern biomarkers into Uzbekistan's healthcare system are substantial, despite the challenges. Public-private partnerships could subsidize the procurement of diagnostic equipment, while international collaborations with organizations like the World Health Organization could support capacity-building for laboratory technicians. Mobile diagnostic units, equipped with portable hematology analyzers, could bridge the urban-rural



divide, enabling CHr and hemoglobin testing in remote areas. Incorporating biomarker testing into national health programs, such as those targeting maternal and child health, could prioritize early anemia detection, reducing complications like maternal mortality and developmental delays in children. Additionally, regional research initiatives could validate biomarker reference ranges, leveraging Uzbekistan's growing academic infrastructure, including institutions like the Tashkent Medical Academy.

Technological advancements offer further promise. Point-of-care (POC) testing platforms, which are portable and cost-effective, could democratize access to biomarkers like sTfR and hepcidin. For example, microfluidic devices and lateral flow assays, currently under development globally, could enable rapid biomarker testing in primary care settings, aligning with Uzbekistan's push for decentralized healthcare. Telemedicine, increasingly adopted in Uzbekistan, could facilitate remote consultation with specialists for interpreting complex biomarker profiles, improving diagnostic accuracy in underserved areas. Moreover, integrating biomarker data with electronic health records, a priority in Uzbekistan's healthcare digitization efforts, could streamline anemia management and enable longitudinal monitoring of at-risk populations.

In conclusion, modern biomarkers—hepcidin, sTfR, CHr, erythroferrone, and GDF-15—represent a paradigm shift in anemia diagnostics, offering unparalleled precision in identifying anemia subtypes and guiding therapy. Their implementation in Uzbekistan, while hindered by economic, infrastructural, and epidemiological challenges, is achievable through strategic investments in technology, training, and research. By aligning biomarker use with local disease patterns and healthcare priorities, Uzbekistan can enhance anemia diagnosis and management, reducing its public health burden and improving quality of life for millions. Future efforts should focus on developing cost-effective diagnostic platforms, validating population-specific reference ranges, and integrating biomarkers into national health strategies to ensure equitable access and sustainable impact.

References:

1. Abdullaev, A. K., & Karimova, N. M. (2020). Prevalence and diagnosis of anemia in Uzbekistan. *Tashkent: Uzbekistan Medical Journal*, 15(3), 45-52.
2. Rakhimov, S. T. (2022). New approaches to the treatment of iron deficiency anemia. *Samarkand: Samarkand State Medical Institute Scientific Bulletin*, 10(2), 78-85.
3. World Health Organization. (2021). *Global anemia reduction efforts: Progress and challenges*. Geneva: WHO Press.

4. Kassebaum, N. J., & GBD 2013 Anemia Collaborators. (2016). The global burden of anemia. *Hematology/Oncology Clinics of North America*, 30(2), 247-308.
5. Nemeth, E., & Ganz, T. (2014). Heparidin and iron homeostasis. *Annual Review of Medicine*, 65, 147-158.
6. Camaschella, C., & Pagani, A. (2018). Advances in understanding iron metabolism and anemia. *Blood*, 131(1), 51-58.

